Previous 10 | Next 10 |
FY 2022 Annual Revenue of $1.032 billion, Up 22% Versus Prior Year ABIOMED, Inc. (NASDAQ: ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announced financial results for the quarter and fiscal year ended March 31, 2022. Financial summ...
Abiomed (NASDAQ:ABMD) is scheduled to announce Q4 earnings results on Thursday, April 28th, before market open. The consensus EPS Estimate is $1.05 (-1.9% Y/Y) and the consensus Revenue Estimate is $267.67M (+11.0% Y/Y). Over the last 2 years, ABMD has beaten EPS estimates 88% of the time and...
Abiomed (Nasdaq: ABMD) announces the first patient in the world has been successfully implanted with Impella Bridge-to-Recovery (BTR) as part of the heart pump’s U.S. Food and Drug Administration (FDA) Early Feasibility Study (EFS). The first implant was done by Duc Thinh Pha...
Abiomed (NASDAQ:ABMD) and AtriCure (NASDAQ:ATRC) were among some of the healthcare equipment makers to earn bullish views at Piper Sandler after the Centers for Medicare and Medicaid Services (CMS) issued its annual Inpatient Prospective Payment System (IPPS) proposed rule on Monday...
Abiomed, Inc . (NASDAQ: ABMD) announced that on Thursday, April 28, 2022, the Company will release financial results for the fourth quarter of the fiscal year 2022. The Company will host a conference call to discuss the results on Thursday, April 28, 2022 at 8:00 a.m. ET. Michael R....
Abiomed (NASDAQ:ABMD) said the first patient in Japan was treated successfully with Impella 5.5 with SmartAssist. Impella 5.5 with SmartAssist is a minimally-invasive forward flow heart pump. The company said first Impella 5.5 with SmartAssist procedure in Japan took place at Osaka Police Hos...
5,000 Patients Treated Globally The versatility and innovation of Abiomed’s (NASDAQ: ABMD) Impella 5.5 with SmartAssist , a minimally-invasive forward flow heart pump, is leading to continued adoption of the game-changing technology by surgeons around the ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Thermo Fisher Scientific ( TMO ): A leader in scientific instrumentation, TMO is a powerhouse among medical device stocks. Edwards Lifesciences ( EW ): Promoting products to help improving cardiovascular dise...
The following slide deck was published by Abiomed, Inc. in conjunction with this event. For further details see: Abiomed (ABMD) Impella ECP Investor Call - Slideshow
Medical device maker, Abiomed (ABMD -3.6%) is in the red after the company announced the retirement of its Chief Operating Officer and Senior Vice President David Weber, after a 15-year tenure. Mr. Weber informed his decision on March 28, the company disclosed in a regulatory filing. After th...
News, Short Squeeze, Breakout and More Instantly...
Abiomed (Nasdaq: ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Amir Kaki, MD, director of mechanical circulatory support...
Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400 Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400 PR Newswire NEW YORK , Dec. 19, 2022 /PRNewswire/ -- S&P MidCap 400 constituent...
Abiomed (Nasdaq: ABMD) announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist, Abiomed’s newest heart pump for patients experiencing right heart failure. All three patients have now been successfully weaned off Impella support and two have...